Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Avigdor

Showing results (21-30 of 118) with videos related to

Pageof 12
Sort By:
Cancer Letters|September 13, 2003
Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemiaOrlev Levy-Nissenbaum, Orit Sagi-Assif, Pia Raanani, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2021
Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction ChemotherapyGal Sharvit, Gabriel Heering, Maya Zlotnik, et al.
Methods in Enzymology|December 17, 2003
cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemiaOrlev Levy-Nissenbaum, Orit Sagi-Assif, Pia Raanani, et al.
British Journal of Haematology|May 28, 2014
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysisMerav Leiba, Meirav Kedmi, Adrian Duek, et al.
Leukemia & Lymphoma|July 10, 2020
Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcomeGuy Bitansky, Abraham Avigdor, Elena Vasilev, et al.
Annals of Hematology|January 6, 2022
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapyNaama Keren-Froim, Gabriel Heering, Gal Sharvit, et al.
Current Research in Translational Medicine|December 29, 2019
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemiaIvetta Danylesko, Guy Chowers, Roni Shouval, et al.
Experimental Hematology|May 24, 2003
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicityAvichai Shimoni, Bella Bielorai, Amos Toren, et al.
Haematologica|December 7, 2022
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantationYaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Scientific Reports|June 11, 2022
Evaluation of the clinical impact of bone marrow cultures in current medical practiceGal Sharvit, Daniel Schwartz, Gabriel Heering, et al.
Pageof 12

Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
Cancer Letters|September 13, 2003
Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemiaOrlev Levy-Nissenbaum, Orit Sagi-Assif, Pia Raanani, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2021
Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction ChemotherapyGal Sharvit, Gabriel Heering, Maya Zlotnik, et al.
Methods in Enzymology|December 17, 2003
cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemiaOrlev Levy-Nissenbaum, Orit Sagi-Assif, Pia Raanani, et al.
British Journal of Haematology|May 28, 2014
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysisMerav Leiba, Meirav Kedmi, Adrian Duek, et al.
Leukemia & Lymphoma|July 10, 2020
Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcomeGuy Bitansky, Abraham Avigdor, Elena Vasilev, et al.
Annals of Hematology|January 6, 2022
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapyNaama Keren-Froim, Gabriel Heering, Gal Sharvit, et al.
Current Research in Translational Medicine|December 29, 2019
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemiaIvetta Danylesko, Guy Chowers, Roni Shouval, et al.
Experimental Hematology|May 24, 2003
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicityAvichai Shimoni, Bella Bielorai, Amos Toren, et al.
Haematologica|December 7, 2022
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantationYaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Scientific Reports|June 11, 2022
Evaluation of the clinical impact of bone marrow cultures in current medical practiceGal Sharvit, Daniel Schwartz, Gabriel Heering, et al.
Pageof 12